Your browser doesn't support javascript.
loading
Assessing Photostability of mAb Formulations In Situ Using Light-Coupled NMR Spectroscopy.
Bramham, Jack E; Wang, Yujing; Moore, Stephanie A; Golovanov, Alexander P.
Afiliación
  • Bramham JE; Department of Chemistry, School of Natural Sciences, Faculty of Science and Engineering, The University of Manchester, Manchester M1 7DN, U.K.
  • Wang Y; Dosage Form Design & Development, BioPharmaceutical Development, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • Moore SA; Dosage Form Design & Development, BioPharmaceutical Development, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • Golovanov AP; Department of Chemistry, School of Natural Sciences, Faculty of Science and Engineering, The University of Manchester, Manchester M1 7DN, U.K.
Anal Chem ; 96(24): 9935-9943, 2024 06 18.
Article en En | MEDLINE | ID: mdl-38847283
ABSTRACT
Biopharmaceuticals, such as monoclonal antibodies (mAbs), need to maintain their chemical and physical stability in formulations throughout their lifecycle. It is known that exposure of mAbs to light, particularly UV, triggers chemical and physical degradation, which can be exacerbated by trace amounts of photosensitizers in the formulation. Although routine assessments of degradation following defined UV dosages are performed, there is a fundamental lack of understanding regarding the intermediates, transient reactive species, and radicals formed during illumination, as well as their lifetimes and immediate impact post-illumination. In this study, we used light-coupled NMR spectroscopy to monitor in situ live spectral changes in sealed samples during and after UV-A illumination of different formulations of four mAbs without added photosensitizers. We observed a complex evolution of spectra, reflecting the appearance within minutes of transient radicals during illumination and persisting for minutes to tens of minutes after the light was switched off. Both mAb and excipient signals were strongly affected by illumination, with some exhibiting fast irreversible photodegradation and others exhibiting partial recovery in the dark. These effects varied depending on the mAb and the presence of excipients, such as polysorbate 80 (PS80) and methionine. Complementary ex situ high-performance size-exclusion chromatography analysis of the same formulations post-UV exposure in the chamber revealed significant loss of purity, confirming formulation-dependent degradation. Both approaches suggested the presence of degradation processes initiated by light but continuing in the dark. Further studies on photoreaction intermediates and transient reactive species may help mitigate the impact of light on biopharmaceutical degradation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rayos Ultravioleta / Anticuerpos Monoclonales Idioma: En Revista: Anal Chem Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Rayos Ultravioleta / Anticuerpos Monoclonales Idioma: En Revista: Anal Chem Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos